前循环缺血性卒中机械取栓术中个体化与标准血压管理对比:DETERMINE随机对照试验
DETERMINE试验为多中心、前瞻性、随机、对照、开放标签、盲法终点(PROBE设计)临床研究,拟纳入432例前循环近端大血管闭塞的急性缺血性卒中患者,1:1随机分为个体化血压管理组(平均动脉压维持在取栓前首次测量值10%以内)与标准血压管理组(收缩压维持在140-180 mm Hg直至再灌注或取栓失败动脉关闭),主要结局为90天改良Rankin量表0-2分的良好功能结局率。
要点
- DETERMINE试验比较取栓术中个体化血压管理(平均动脉压维持在首次测量值10%以内)与标准血压管理(收缩压140-180 mm Hg)。
- 主要结局为90天改良Rankin量表0-2分的良好功能结局率,拟纳入432例前循环近端大血管闭塞患者。
- 试验旨在评估个体化血压管理相比现行国际指南推荐的一刀切方案在再灌注前的临床相关性。
核心结论
- DETERMINE试验将评估再灌注前个体化血压管理相较于国际指南目前推荐的一刀切方案的临床相关性。
研究设计与样本
- 多中心、前瞻性、随机、对照、开放标签、盲法终点临床试验(PROBE设计),拟纳入432例前循环近端大血管闭塞的急性缺血性卒中患者,1:1随机分组。
主要发现
- 试验组平均动脉压维持在取栓前首次测量值10%以内,对照组收缩压维持在140-180 mm Hg直至再灌注或取栓失败动脉关闭。
- 主要结局为90天改良Rankin量表0-2分的良好功能结局率。
- 次要结局包括90天极佳结局与改良Rankin量表序贯分析、24小时早期神经功能改善(美国国立卫生研究院卒中量表)、最终梗死体积、症状性颅内出血率及90天全因死亡率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypotension and blood pressure (BP) variability during endovascular therapy (EVT) for acute ischemic stroke (AIS) due to an anterior large vessel occlusion (LVO) is associated with worse outcomes. However, the optimal BP threshold during EVT is still unknown given the lack of randomized controlled evidence. We designed the DETERMINE trial to assess whether an individualized BP management during EVT could achieve better functional outcomes compared to a standard BP management. METHODS: The DETERMINE trial is a multicenter, prospective, randomized, controlled, open-label, blinded endpoint clinical trial (PROBE design). AIS patients with a proximal anterior LVO are randomly assigned, in a 1:1 ratio, to an experimental arm in which mean arterial pressure (MAP) is maintained within 10% of the first MAP measured before EVT, or a control arm in which systolic BP (SBP) is maintained within 140-180 mm Hg until reperfusion is achieved or artery closure in case of EVT failure. The primary outcome is the rate of favorable functional outcomes, defined by a modified Rankin Scale (mRS) between 0 and 2 at 90 days. Secondary outcomes include excellent outcome and ordinal analysis of the mRS at 90 days, early neurological improvement at 24 h (National Institutes of Health Stroke Scale), final infarct volume, symptomatic intracranial hemorrhage rates, and all-cause mortality at 90 days. Overall, 432 patients will be included. DISCUSSION: DETERMINE will assess the clinical relevance of an individualized BP management before reperfusion compared to the one size fits all approach currently recommended by international guidelines. TRIAL REGISTRATION: ClinicalTrials.gov , NCT04352296. Registered on 20th April 2020.
引用
- Maïer B, Gory B, Chabanne R, et al. Effect of an individualized versus standard blood pressure management during mechanical thrombectomy for anterior ischemic stroke: the DETERMINE randomized controlled trial. Trials. 2022. PMID: 35883180. doi:10.1186/s13063-022-06538-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。